Columbia Wanger Asset Management
KITE

Columbia Wanger Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Columbia Wanger Asset Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-368,254
Closed -$38.2M – 219
2017
Q2 		$38.2M Sell
368,254
-83,420
-18% -$6.81M 0.54% 75
2017
Q1 		$35.5M Buy
+451,674
New +$27.9M 0.5% 97

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Columbia Wanger Asset Management's KITE Position: Q3 2017 in Review

Columbia Wanger Asset Management sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 368,254 shares — an estimated $38.2M sold.

Columbia Wanger Asset Management first reported a position in KITE in Q1 2017 and held it in 2 quarters. The position peaked at $38.2M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Columbia Wanger Asset Management reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Columbia Wanger Asset Management sold 368,254 Kite Pharma, Inc. shares in Q3 2017, an estimated $38.2M.
  • Columbia Wanger Asset Management first reported a position in Kite Pharma, Inc. in Q1 2017 and held it in 2 quarters.
  • Columbia Wanger Asset Management's Kite Pharma, Inc. position peaked at $38.2M in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Columbia Wanger Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.